Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8035545 | 0.82 | CES2 (0.32) | CES2CES1ALDH1A1CA12CA1 | |
| SCHEMBL19968364 | 0.73 | CES2 (0.33) | CES2CES1ALDH1A1CA12CA1 | |
| SCHEMBL1041954 | 0.71 | CES2 (0.32) | CES2CES1ALDH1A1CA12CA1 | |
| SCHEMBL2881917 | 0.67 | CA12 (0.38) | CES2CES1CA12CA1CA9 | |
| SCHEMBL22984483 | 0.65 | RAPGEF4 (0.34) | — | |
| SCHEMBL19968258 | 0.65 | ERN1 (0.31) | ERN1 | |
| SCHEMBL2883739 | 0.65 | ALDH1A1 (0.42) | CES2CES1ALDH1A1CA9 | |
| SCHEMBL29349450 | 0.65 | ALDH1A1 (0.42) | CES2CES1ALDH1A1CA9 | |
| SCHEMBL1043332 | 0.65 | CES2 (0.36) | CES2CES1ALDH1A1CA12CA1 | |
| SCHEMBL531337 | 0.63 | CES2 (0.52) | CES2CES1ALDH1A1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113896607-B | Olefin oligomerization process using a catalyst comprising a chromium complex having a phosphacycle-containing ligand | 陶氏环球技术有限责任公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-107548385-B | Olefin oligomerization process using catalyst comprising chromium complex with phosphacycle-containing ligand | 陶氏环球技术有限责任公司 | 2022-01-21 | — | — | CN | disclosed |
| US-7915455-B2 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-03-29 | — | — | US | disclosed |
| EP-2272852-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | Sumitomo Chemical Company, Limited (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20090143620-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED | 2009-06-04 | — | — | US | disclosed |
| US-7482414-B2 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-01-27 | — | — | US | disclosed |
| US-20070135600-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-06-14 | — | — | US | disclosed |
| EP-1683802-A1 | TRANSITION METAL COMPLEX LIGAND AND OLEFIN POLYMERIZATION CATALYST CONTAINING TRANSITION METAL COMPLEX | Sumitomo Chemical Company, Limited (JP) | 2006-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135600-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | AP1M1, OR10J3, AP2M1 | CES2 4628/4885CES1 4598/4885ALDH1A1 4017/4885 |
| US-20090143620-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | AP1M1, OR10J3, AP2M1 | CES2 4628/4885CES1 4598/4885ALDH1A1 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.